(Q34502608)

2 August 2017

title

SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells (English)

1 reference

2 August 2017

Yao Guo

1

1 reference

2 August 2017

Yun Chen

2

1 reference

2 August 2017

Xuesong Xu

3

1 reference

2 August 2017

Xueqi Fu

4

1 reference

2 August 2017

Zhizhuang Joe Zhao

5

1 reference

2 August 2017

publication date

6 December 2012

1 reference

Journal of Hematology & Oncology

2 August 2017

published in

1 reference

2 August 2017

volume

5

1 reference

2 August 2017

page(s)

72

1 reference

JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines

2 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3524753

Generation and characterization of a highly effective protein substrate for analysis of FLT3 activity

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3524753

FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3524753

Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3524753

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3524753

Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3524753

Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3524753

Current findings for recurring mutations in acute myeloid leukemia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3524753

Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3524753

FLT3 as a therapeutic target in AML: still challenging after all these years

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3524753

Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3524753

Bench to bedside targeting of FLT3 in acute leukemia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3524753

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3524753

Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3524753

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3524753

Characterization of a highly effective protein substrate for analysis of JAK2(V617F) Activity

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3524753

Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3524753

7 July 2018

Acute myeloid leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3524753

The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3524753

The role of FLT3 in haematopoietic malignancies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3524753

FLT3 mutations in acute myeloid leukemia cell lines

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3524753

Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia.

7 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1756-8722-5-72

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1756-8722-5-72

Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1756-8722-5-72

Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23216927

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1756-8722-5-72

1 reference

Dimensions Publication ID

2 August 2017

1043945815

0 references

Fatcat ID

release_abd4rdto5vf2zkpklzppeflz2i

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/abd4rdto5vf2zkpklzppeflz2i

mapped directly with Wikidata item

24 November 2022

based on heuristic

PMC publication ID

3524753

1 reference

2 August 2017

1 reference